Journals / 7tepe Klinik / 2019 / Cilt: 15 - Sayı: 3

Drugs used in the treatment of oral mucosal diseases

Oral mukoza hastalıklarının tedavisinde kullanılan ilaçlar

Pages
366–373
Publication Date
2022-09-03
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we aimedto review the drugs used in oral mucosal diseases by thedentists who frequently deal with them.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The oral mucosa and the surrounding tissues are the entranceto the body, where oral mucosa-specific lesionscan be seen, and where symptoms or signs of manysystemic diseases can be observed.
📊
Key Findings & Data:The etiology of thelesions occurring in the oral mucosa may be trauma, infection,immunological causes or idiopathic.
💡
Conclusion & Impact:In this review, we aimedto review the drugs used in oral mucosal diseases by thedentists who frequently deal with them.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The oral mucosa and the surrounding tissues are the entranceto the body, where oral mucosa-specific lesionscan be seen, and where symptoms or signs of manysystemic diseases can be observed. The etiology of thelesions occurring in the oral mucosa may be trauma, infection,immunological causes or idiopathic. Drug applicationonto the mucosa covering the oral cavity haslong been a field of pharmacology. Lesions that occur asa symptom of systemic diseases are usually seen as ulcerations.The purpose of the treatment is to apply symptomatictreatments that mainly improve the patient’scomfort while solving the underlying problem. These areachieved primarily by correcting oral hygiene, regulatingthe diet, and prescribing medicines in the appropriatemanner mentioned in the article. In this review, we aimedto review the drugs used in oral mucosal diseases by thedentists who frequently deal with them.

Özet

Oral mukoza ve çevre dokular çok sayıda sistemik hastalığın belirtilerinin görülebildiği bir bölge olduğu gibi sadece oral mukozaya özgü lezyonların meydana geldiği, vücudun giriş kapısıdır. Ağız mukozasında görülen lezyonların etkeni travma, enfeksiyon, immünolojik ve idiyopatik nedenler olabilir. Oral kaviteyi örten mukoza üzerinde ilaç uygulaması eskiden beri farmakolojinin uğraşı alanı olmuştur. Sistemik hastalıkların belirtisi olarak meydana gelen lezyonlar genelde ülserasyonlar şeklinde görülmektedir. Tedavide hedef, esas olarak altta yatan sebebi çözmekle beraber hasta konforunu arttıran semptomatik tedaviler uygulamaktır. Bunlar başta ağız hijyenini düzeltmek, diyeti düzenlemekle birlikte yazıda belirtilen ilaçların uygun bir şekilde reçete edilmesiyle sağlanır. Bu derlemede oral mukozal hastalıklarla sıklıkla karşılaşan diş hekimlerinin, tedavide uygulamaları gereken ilaçlar hakkında detaylı bilgi verilmesi amaçlanmıştır.

🔖

Cite This Article

ÜNÜR, M., KARAPINAR, G. (2022). Drugs used in the treatment of oral mucosal diseases. 7tepe Klinik, Cilt: 15 - Sayı: 3, 366–373. https://ajindex.com/articles/426071

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Şahin ÖK, Aksoy MÇ. Oral cerrahi işlemler sonrası yara iyileşmesine sigaranın etkileri. Atatürk Üniv Diş Hek Fak Derg 2014; 24: 3
  2. Aksoy H, Özakpınar, ÖB. Yara iyileşmesi ve oksidatif stres. Marmara Pharmaceutical Journal 2014;18:153- 158
  3. Ghosh K, Clark RA. Principles of tissue engineering. Editör: Lanza R, Langer R and Vacanti J. Wound Repair. II. Basic biology of wound repair, Elsevier Academic Press, 2007; 3rd Edition,p.1149-1161
  4. Sen CK, Roy S. Redox signals in wound healing. Biochim Biophys Acta 2008; 1780: 1348-1356
  5. Guo SA, DiPietro, LA. Factors affecting wound healing.L Dent Res 2010; 9: 219-229
  6. Gorski, J, Gannon, F. Current models of steroid hormone action: a critique. Annu Rev Physiol 1976; 38: 425- 450
  7. Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther 2017; 39: 2216-2229
  8. Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am 2010; 43:7 53-768
  9. Caplan A, Fett N, Rosenbach M, Werth, VP, Micheletti R. G. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol 2017; 76: 1-9
  10. Savage NW, McCullough, MJ.Topical corticosteroids in dental practice. Aust Dent J 2005;50: S40-S44. 11.Piñas L, García-García A, Pérez-Sayáns M, Suárez-Fernández R, Alkhraisat MH, Anitua E. The use of topical corticosteroides in the treatment of oral lichen planus in Spain: A national survey. Med Oral Patol Oral Cir Bucal 2017; 22: e264-e269
  11. Gonzalez‐Moles MA, Bravo M, Gonzalez‐Ruiz L, Ramos P, Gil‐Montoya JA. Outcomes of oral lichen planus and oral lichenoid lesions treated with topical corticosteroid. Oral Diseases 2018; 24: 573-579
  12. Lozada-Nur, F., Miranda, C., & Maliksi, R. Double-blind clinical trial of 0.05% clobetasol proprionate ointment in orabase and 0.05% Fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol and Oral Radiol 1994; 77: 598-604
  13. Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med 1992; 21: 456-458
  14. Ceschel GC, Maffei P, Borgia SL, Ronchi C. Design and evaluation of buccal adhesive hydrocortisone acetate (HCA) tablets. Drug Delivery 200